Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropivacaine + tranexamic acid is a pharmacological combination consisting of a long-acting amide-type local anesthetic and a synthetic derivative of the amino acid lysine that acts as an antifibrinolytic. This combination is frequently employed as a periarticular cocktail injection or topical application during orthopedic procedures, specifically total knee arthroplasty (TKA). Ropivacaine provides regional analgesia by reversibly blocking sodium channels in nerve fibers, thereby inhibiting the conduction of pain impulses. Tranexamic acid reduces surgical and postoperative blood loss by competitively inhibiting the activation of plasminogen to plasmin, which prevents fibrinolysis and stabilizes clot formation. Clinical research, including studies at The First Affiliated Hospital of Bengbu Medical College, has evaluated this combination for its ability to enhance postoperative recovery by simultaneously addressing pain management and hemostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + tranexamic acid.